| Description |
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1].
|
| Related Catalog |
|
| In Vitro |
Leronlimab (1-140 mg/mL) 结合 CCR5 阳性细胞高达 98%[1]。 Leronlimab (80-1750 μg/mL) 阻断 MDA-MB-231 细胞中 CCL5，CCL3 和 CCL4 诱导的钙反应[1]。 Leronlimab (175 和 350 mg/mL) 阻断 MDA-MB-231 细胞侵袭[1]。 Leronlimab (10 μg/mL；72 小时) 增强 doxorubicin 对 MDA-MB-231 细胞的细胞毒性[1]。 Cell Cytotoxicity Assay[1] Cell Line: MDA-MB-231 cell line Concentration: 10 μg/mL Incubation Time: 72 hours Result: Increased the cells killing effect induced by doxorubicin.
|
| In Vivo |
Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况[1]。 Animal Model: Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection[1] Dosage: 2 mg Administration: Intraperitoneal injection; 2 mg, twice a week Result: Reduced the volume of pulmonary metastases at 8 weeks.
|
| References |
[1]. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11.
|
